Globus Medical price target raised to $105 from $90 at Canaccord

Canaccord analyst Caitlin Cronin raised the firm’s price target on Globus Medical (GMED) to $105 from $90 and keeps a Buy rating on the shares. The firm said they are bullish on the Med-Tech sector heading into 2026 as they expect investor interest given smid-cap valuations continue to remain depressed, while M&A has picked up and the IPO market has opened in some respects. They also highlight how AI is changing our space, enabling improved patient outcomes, increased procedure volumes, more efficiency at the corporate level, and improved surgical accuracy/reproducibility, which they believe could drive some of the greatest changes in healthcare at a time when the system is capacity constrained and in desperate need of solutions.